Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and ...

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying ...

已保存。查看收藏列表。 Processa Pharmaceuticals, Inc.（纳斯达克股票代码：PCSA）的首席商务和战略官Patrick ...

David Young, the President of Research & Development at Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), has increased his ...

根据最近的SEC文件显示，Processa Pharmaceuticals, Inc. (NASDAQ: PCSA )研发部门总裁David Young最近增加了他在公司的持股。Young以每股0.7975美元的价格购买了124,500股普通股，交易总额为99,288美元。这次购买使Young的直接持股增加到205,405股。

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused ...

The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the ...

Processa Pharmaceuticals (PCSA) announced the pricing of its “reasonable best efforts” public offering with participation from the Company’s ...

Processa Pharmaceuticals, Inc. has successfully completed a public offering, raising $5 million to support its development of next-generation chemotherapeutic drugs aimed at improving efficacy and ...

Processa Pharmaceuticals Inc. (PCSA) stock has tumbled to a 52-week low, touching down at $0.65, with InvestingPro data ...

Processa Pharmaceuticals, Inc. announced the pricing of a public offering aimed at raising approximately $5 million, with participation from its CEO, board members, and institutional investors.

HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next ...